<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775759</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00072372</org_study_id>
    <nct_id>NCT03775759</nct_id>
  </id_info>
  <brief_title>Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study</brief_title>
  <acronym>TVVAD</acronym>
  <official_title>Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the utility of tricuspid valve repair at the time&#xD;
      of LVAD implantation for patients presenting with moderate or severe tricuspid regurgitation.&#xD;
      The study will be a randomized trial for patients presenting for LVAD implantation to either&#xD;
      tricuspid valve repair or no tricuspid valve repair. The data will be analyzed as both an&#xD;
      intention to treat analysis as well as an &quot;as treated&quot; analysis with the primary outcome&#xD;
      being rates of right ventricular dysfunction post LVAD implantation. Tricuspid valve repair&#xD;
      for these patient is currently being done for some patients, without any strong data to&#xD;
      either support such practice or negate it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single center, randomized trial. Up to 280 subjects will be&#xD;
      enrolled.&#xD;
&#xD;
      Inclusion Criteria - Potential subjects must meet all inclusion criteria to participate.&#xD;
&#xD;
        -  Planned LVAD implantation (either destination or bridge indication)&#xD;
&#xD;
        -  18 years of age or older&#xD;
&#xD;
        -  Patients wilith mild tricuspid regurgitation (TR) during surgical planning will be&#xD;
           screened for meeting inclusion criteria for this study.&#xD;
&#xD;
        -  TR on pre-operative echo (within one week of procedure) (TTE or intraoperative TEE)&#xD;
           quantified as moderate or severe with normal tricuspid valve leaflets&#xD;
&#xD;
      Exclusion Criteria&#xD;
&#xD;
        -  Previous tricuspid valve surgery&#xD;
&#xD;
        -  Previous LVAD&#xD;
&#xD;
        -  Planned concurrent right ventricular assist device (RVAD) or extracorporeal membrane&#xD;
           oxygenation (ECMO) at the time of LVAD operation or during the same hospitalization&#xD;
&#xD;
        -  Preimplant RVAD or ECMO&#xD;
&#xD;
        -  Planned thoracotomy approach for LVAD implantation&#xD;
&#xD;
        -  Pregnant women&#xD;
&#xD;
      All subjects will undergo an intraoperative transesophageal echocardiogram (TEE) to evaluate&#xD;
      their tricuspid valve. Subjects will be randomized in the operating room. Randomization will&#xD;
      be stratified based on preoperative right ventricle dysfunction. Subjects will be randomized&#xD;
      1:1 to either of the following treatment arms:&#xD;
&#xD;
        -  Study arm (Arm A) - Tricuspid valve ring annuloplasty or replacement at the time of LVAD&#xD;
           implantation plus medical therapy&#xD;
&#xD;
        -  Control arm (Arm B) - LVAD implantation plus medical therapy (the medical therapy&#xD;
           involved includes inotropic medications and diuretic medications, which are standard of&#xD;
           care for patients in this population)&#xD;
&#xD;
      Subjects will be monitored in the surgical and on the step down floor ICU, and follow-up data&#xD;
      will be collected on subjects monthly from routine tests and clinic visits. This will include&#xD;
      information on adverse events and any hospital readmissions, a quality of life questionnaire&#xD;
      at their 6 month visit, and a six minute walk test at three and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled, non-blinded, single center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients experiencing moderate or greater right heart failure within 6 months post-operatively</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Patients experiencing moderate or greater right heart failure as defined by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Right Heart Failure</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tricuspid valve ring annuloplasty or replacement at the time of LVAD implantation plus medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LVAD implantation plus medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tricuspid valve repair or replacement</intervention_name>
    <description>Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical management of tricuspid regurgitation</intervention_name>
    <description>The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned LVAD implantation (either destination or bridge indication)&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Patients will mild tricuspid regurgitation (TR) during surgical planning will be&#xD;
             screened for meeting inclusion criteria for this study.&#xD;
&#xD;
          -  Patients with moderate or graeter TR on pre-operative echo (within one week of&#xD;
             procedure) (TTE or intraoperative TEE) will qualify for randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous tricuspid valve surgery&#xD;
&#xD;
          -  Previous left ventricular assist device&#xD;
&#xD;
          -  Planned concurrent right ventricular assist device (RVAD) or extracorporeal membrane&#xD;
             oxygenation (ECMO) at the time of LVAD operation or during the same hospitalization&#xD;
&#xD;
          -  Preimplant RVAD or ECMO&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Mendiola Pla, M.D.</last_name>
    <phone>310-746-7294</phone>
    <email>michelle.mendiola.pla@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmelo Milano, M.D.</last_name>
    <phone>919-684-3243</phone>
    <email>carmelo.milano@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mendiola Pla, M.D.</last_name>
      <phone>310-746-7294</phone>
      <email>michelle.mendiola.pla@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Muath Bishawi, M.D.</last_name>
      <phone>631-578-2092</phone>
      <email>muath.bishawi@duke.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left ventricular assist device</keyword>
  <keyword>Tricuspid regurgitation</keyword>
  <keyword>Right heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

